nemtabrutinib (arq 531) in covalent btki resistant cll
Published 4 years ago • 169 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
1:12
pirtobrutinib vs nemtabrutinib in cll
-
2:17
updated analysis of bellwave-001: nemtabrutinib in r/r cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:28
bellwave-001: nemtabrutinib in patients with r/r cll/sll
-
1:32
an update from bellwave-001: nemtabrutinib in cll/sll
-
1:29
bellwave-011: nemtabrutinib vs ibrutinib/acalabrutinib in treatment-naïve cll/sll
-
2:08
cll-rt1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with rt
-
0:58
alpine: qol in patients with r/r cll treated with zanubrutinib vs ibrutinib
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
1:28
quizartinib provides clinical benefit in r/r flt3-itd aml
-
6:24
gilteritinib in r/r aml
-
0:52
combining pembrolizumab with bcr inhibitors for richter's transformation
-
1:50
progress for gilteritinib and quizartinib for aml in the first-line setting
-
2:30
blinatumomab for relapsed/refractory burkitt's lymphoma
-
3:12
total serum bilirubin meter - oet-tb10
-
1:31
azacitidine and venetoclax plus gilteritinib in the treatment of flt3-mutated aml